BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike

Reuters12-12 23:11
BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For <a href="https://laohu8.com/S/MRNA">Moderna</a>'s Mnexspike

Dec 12 (Reuters) - EMA's CHMP:

  • EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR MNEXSPIKE, FOR PREVENTION OF COVID-19 IN PEOPLE FROM 12 YEARS OF AGE

  • EMA'S CHMP: RECOMMENDED CHANGE TO EXTEND USE OF MOUNJARO FOR TREATMENT OF A TYPE OF TYPE 2 DIABETES

  • EMA'S CHMP: EXDENSUR (DEPEMOKIMAB) RECEIVED A POSITIVE OPINION

  • EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR UPLIZNA

  • EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR NUCALA

  • EMA'S CHMP: ADOPTED A POSITIVE OPINION FOR MYQORZO FOR TREATMENT OF ADULTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

  • EMA'S CHMP: CONCLUDES REFERRAL FOR MELATOMED, RECOMMENDS MARKETING AUTHORISATION CAN BE GRANTED

  • EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR AREXVY, ASPAVELI, DOVPRELA, ELUCIREM, EYLEA, NUCALA, RECARBRIO, SIMPONI, UPLIZNA, VUEWAY

Further company coverage: MRNA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment